NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company
developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported
biomarker data from a pilot trial of AT-007 in patients with SORD Deficiency.

See the complete Press Release.

More on SORD